MYDA Advisors’s Relmada Therapeutics RLMD Stock Holding History

MYDA Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,000	Closed	-$273K	–	158
2019 Q4	$273K	Buy	+7,000	New	+$213K	0.12%	94

Other funds holding RLMD

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MYDA Advisors's RLMD Position: Q1 2020 in Review

MYDA Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2020, closing a stake of 7,000 shares — an estimated $273K sold.

MYDA Advisors first reported a position in RLMD in Q4 2019 and held it in 1 quarter. The position peaked at $273K in Q4 2019. 43 funds tracked by Wall St. Rank hold RLMD as of Q1 2020.

MYDA Advisors reported no remaining Relmada Therapeutics position as of Q1 2020 after selling out during the quarter.
MYDA Advisors sold 7,000 Relmada Therapeutics shares in Q1 2020, an estimated $273K.
MYDA Advisors first reported a position in Relmada Therapeutics in Q4 2019 and held it in 1 quarter.
MYDA Advisors's Relmada Therapeutics position peaked at $273K in Q4 2019.
43 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.